Abstract
Objectives: In prospective trials, episodic valaciclovir significantly increased the chance of preventing or aborting the development of painful vesicular genital herpes simplex virus (HSV) lesions compared with placebo. We explored the clinical outcome of aborted lesions and its association with early treatment in a study designed to compare 3 and 5 days' treatment with valaciclovir.
Methods: In a randomised controlled trial, valaciclovir 500 mg twice daily for 3 or 5 days was initiated at the first symptoms of a genital herpes outbreak. The primary end point was length of episode with pain, HSV shedding, and aborted lesions secondary end points. The effect of time from symptom recognition to treatment initiation on aborted lesions was assessed in a post hoc analysis.
Results: In 531 patients, no differences were observed between 3 and 5 days' treatment in episode duration (median 4.7 v 4.6 days), loss of pain/discomfort (2.8 v 3.0 days), or lesion healing (4.9 v 4.5 days). Vesicular lesions were aborted in 27% of patients treated for 3 days v 21% of patients receiving valaciclovir for 5 days. The odds of achieving an aborted episode were 1.93 (95% CI: 1.28 to 2.90) times higher for those initiating treatment with valaciclovir within 6 hours of first sign or symptom.
Conclusions: There was no difference between 3 and 5 days' treatment in reducing episode duration or lesion abortion. Prompt treatment with valaciclovir can abort genital HSV reactivation episodes, preventing a vesicular outbreak. Maximum treatment benefit depends on prompt therapy after recognition of symptoms.
Full Text
The Full Text of this article is available as a PDF (163.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodsworth N. J., Crooks R. J., Borelli S., Vejlsgaard G., Paavonen J., Worm A. M., Uexkull N., Esmann J., Strand A., Ingamells A. J. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med. 1997 Apr;73(2):110–116. doi: 10.1136/sti.73.2.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Corey L. The current trend in genital herpes. Progress in prevention. Sex Transm Dis. 1994 Mar-Apr;21(2 Suppl):S38–S44. [PubMed] [Google Scholar]
- Goldberg L. H., Kaufman R., Conant M. A., Sperber J., Allen M. L., Illeman M., Chapman S. Oral acyclovir for episodic treatment of recurrent genital herpes. Efficacy and safety. J Am Acad Dermatol. 1986 Aug;15(2 Pt 1):256–264. doi: 10.1016/s0190-9622(86)70165-5. [DOI] [PubMed] [Google Scholar]
- Mertz G. J., Benedetti J., Ashley R., Selke S. A., Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992 Feb 1;116(3):197–202. doi: 10.7326/0003-4819-116-3-197. [DOI] [PubMed] [Google Scholar]
- Nilsen A. E., Aasen T., Halsos A. M., Kinge B. R., Tjøtta E. A., Wikström K., Fiddian A. P. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet. 1982 Sep 11;2(8298):571–573. doi: 10.1016/s0140-6736(82)90658-4. [DOI] [PubMed] [Google Scholar]
- Reichman R. C., Badger G. J., Mertz G. J., Corey L., Richman D. D., Connor J. D., Redfield D., Savoia M. C., Oxman M. N., Bryson Y. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA. 1984 Apr 27;251(16):2103–2107. [PubMed] [Google Scholar]
- Ruhnek-Forsbeck M., Sandström E., Andersson B., Eriksson G., Hersle K., Lövhagen G. B., Mobacken H., Hillström L., Svensson L. Treatment of recurrent genital herpes simplex infections with oral acyclovir. J Antimicrob Chemother. 1985 Nov;16(5):621–628. doi: 10.1093/jac/16.5.621. [DOI] [PubMed] [Google Scholar]
- Spruance S. L., Tyring S. K., DeGregorio B., Miller C., Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med. 1996 Aug 12;156(15):1729–1735. [PubMed] [Google Scholar]
- Tyring S. K., Douglas J. M., Jr, Corey L., Spruance S. L., Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Arch Dermatol. 1998 Feb;134(2):185–191. doi: 10.1001/archderm.134.2.185. [DOI] [PubMed] [Google Scholar]
- Whatley J. D., Thin R. N. Episodic acyclovir therapy to abort recurrent attacks of genital herpes simplex infection. J Antimicrob Chemother. 1991 May;27(5):677–681. doi: 10.1093/jac/27.5.677. [DOI] [PubMed] [Google Scholar]